Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future potential through projected earnings and sales growth [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines the three Style Scores to highlight stocks with attractive value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [7] - There are typically over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down their choices [8] - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: HealthEquity (HQY) - HealthEquity, based in Draper, UT, provides integrated healthcare account management solutions and is rated 2 (Buy) with a VGM Score of B [11] - The company is positioned well for growth, with a Growth Style Score of B and a projected year-over-year earnings growth of 19.6% for the current fiscal year [12] - Recent analyst revisions have increased the earnings estimate for fiscal 2026 by $0.11 to $3.73 per share, alongside an average earnings surprise of +12.4% [12]

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors about its financial health and growth prospects, leading to a significant drop in stock price [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1][2]. - The allegations center around claims that Centene and its executives provided an overly optimistic view of the company's financial situation, particularly regarding revenue outlook and enrollment rates [3][4]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, stating that market growth across 22 states, which accounts for 72% of its marketplace membership, was "lower than expected," leading to a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price fell by more than 40%, resulting in billions of dollars in lost shareholder value [5]. Group 3: Investigative Actions - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][6]. - The firm suggests that if the allegations are proven true, they indicate a disconnect between Centene's public statements and its actual performance metrics [6].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to a significant drop in its stock price, with allegations of misleading investors about the company's financial health and growth prospects during a specified class period [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1][2]. - Accusations include that Centene and its executives presented an overly optimistic view of the company's financial status, claiming reliable information about projected revenue and growth while actual metrics indicated lower enrollment and increased morbidity [3][4]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states, which account for 72% of its marketplace membership, was lower than expected, leading to a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price fell by over 40%, resulting in billions of dollars in lost shareholder value [5]. Group 3: Investigation and Response - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][6]. - The firm suggests that if the allegations are proven true, they indicate a disconnect between Centene's public statements and its internal performance metrics, potentially leaving investors at a loss [6].

Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call. Up ...

Veteran Dealmaker Brings More Than 25 Years of Healthcare Industry Experience Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high net-worth individuals, families, corporate executives, local governments, businesses and institutions. Media Contact: Joseph Kuo / Michael Dugan Haven Tower Gro ...

Investment Rating - The report maintains a "Buy" rating for Asymchem, Kangji Medical, Weigao, Angelalign, and Hygeia, while Tigermed, WuXi XDC, WuXi Biologics, and Frontage are rated as "Neutral" [11][15][18][27][36]. Core Insights - The report highlights a recovery in the healthcare sector, particularly in the CDMO segment, with expectations for earnings resilience driven by new order growth and demand from both US and EU markets, as well as from Chinese biotech licensing [2][3]. - The Medtech sector is anticipated to see clearer recovery in the second half of 2025, supported by normalized hospital activity and new product contributions [3]. - The report emphasizes the importance of monitoring pricing competition and consumption recovery signals in the services sector, particularly in consumer-related categories [4]. Summary by Sections CRO/CDMO - Earnings are expected to remain resilient, especially for companies with exposure to late-stage development and manufacturing projects [2]. - Key investor focus areas include new order growth, client behavior shifts amid policy uncertainties, and pricing and margin recovery [2][13]. - EPS estimates have been revised upward by an average of 1.3% to 1.4% for 2025-2027, with target prices adjusted by an average of 4% [1]. Medtech - Recovery is expected to materialize more clearly in the second half of 2025, with key areas to watch including the pace of VBP rollout and surgical volume trends [3]. - Companies like Weigao and Kangji are ramping up new product launches and global expansions, despite some tariff-related uncertainties [3]. Services - Reimbursement control and DRG/DIP pressure are likely to persist, impacting pricing and volumes [4]. - The report notes a cautious outlook for M&A activity, with companies like Hygeia becoming more positive while others remain cautious [9]. Financial Estimates - The report provides detailed financial estimates for various companies, indicating expected sales growth and net income projections for FY25 and beyond [14][19]. - For instance, WuXi Apptec is projected to achieve a revenue growth of 10-15% for FY25, while Asymchem anticipates double-digit revenue growth alongside margin improvements [19]. Target Price Changes - Target prices for several companies have been adjusted, with Asymchem's target price increased to HK$85.5, reflecting a 13% change [11][15]. - WuXi Biologics' target price is set at HK$25.6, based on a 12-month forward P/E of 22x [15][31]. Backlog and Order Trajectory - The report includes a detailed analysis of backlog and new order trajectories for key players in the CRO/CDMO space, indicating significant year-on-year growth in sales and backlog for companies like WuXi Apptec and WuXi Biologics [17].

Core Viewpoint - The Centene class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, leading to significant financial losses for shareholders [4][5]. Company Overview - Centene Corporation is a healthcare enterprise that provides integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Allegations of the Lawsuit - The lawsuit claims that Centene created a false impression of reliable revenue projections and growth while overstating enrollment rates and underreporting morbidity [4]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than expected, which led to a reduction in its guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price fell by more than 40% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Centene securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Kaskela Law LLC is investigating National HealthCare Corporation (NHC) due to a significant decline in its stock price, which has dropped nearly 20% since November 2024 [1][2]. Group 1: Stock Performance - NHC's common stock has decreased from over $135.00 per share to below $110.00 per share, representing a decline of nearly 20% in value [1]. Group 2: Legal Investigation - The investigation aims to determine if NHC and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2]. - Shareholders of NHC are encouraged to contact Kaskela Law LLC for more information regarding their legal rights and options [2].

Core Viewpoint - The Centene class action lawsuit alleges that Centene Corporation and its executives misled investors regarding the company's revenue outlook and growth potential during the specified class period, leading to significant financial losses for shareholders [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Lunstrum v. Centene Corporation and covers the period from December 12, 2024, to June 30, 2025 [1]. - The lawsuit claims that Centene provided false information about its projected revenue and growth, particularly regarding enrollment rates and morbidity [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, resulting in a significant stock price drop of over 40% [4]. Group 2: Financial Impact - The preliminary analysis indicated that over two-thirds of Centene's marketplace share showed lower-than-anticipated enrollment and increased morbidity, contradicting the company's optimistic reports [3]. - Following the withdrawal of guidance, Centene's adjusted diluted EPS was reduced to approximately $2.75, with a total guidance reduction to about $1.8 billion [4]. Group 3: Legal Process - Investors who suffered losses during the class period can seek to become the lead plaintiff in the lawsuit, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to be the lead plaintiff to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for securing significant monetary relief for investors and has a strong track record in handling large securities class action recoveries [6].

Core Insights - AMN Healthcare Services, Inc. announced the sale of its Smart Square scheduling software to symplr for $75 million, establishing a commercial partnership to enhance operational technology and workforce solutions [1][10] - The partnership is expected to strengthen AMN's Scheduling and Staff Planning business, boosting its position in the healthcare workforce management niche [2] Company Performance - Following the announcement, AMN's shares gained nearly 0.5%, reflecting positive market sentiment [3] - AMN Healthcare has a market capitalization of $843.9 million and an earnings yield of 4.8%, outperforming the industry average of 4.2% [4] Strategic Rationale - AMN Healthcare aims to meet the increasing demand for integrated workforce management solutions by combining its capabilities with symplr's software, which is expected to streamline various administrative processes for healthcare organizations [5][6] - The partnership is anticipated to enhance AMN's WorkWise technology suite, providing clients with a comprehensive solution for workforce management [6] Industry Outlook - The global workforce management market was valued at $8.07 billion in 2022 and is projected to reach $19.35 billion by 2030, growing at a CAGR of 11.7%, driven by workforce optimization and technological advancements [8] - The recent announcement is expected to significantly boost AMN Healthcare's business in light of the market potential [8] Recent Developments - In May, AMN reported a 4.9% year-over-year increase in revenues from its Technology and Workforce Solutions segment's Language services [9]